Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Norway

Research and Innovation Action · Running

ECOPOP Early Colorectal Cancer: Patient-targeted and Organ Preserving Treatment Ecopop

Coordinator
Universitetet I Oslo, Norway
Runs
1 January 2025 to 31 December 2029
Status
Running
EU funding
€7.0m
Total cost
—
Partners
18 organisations in 10 countries
Type
Research and Innovation Action
Grant agreement
101156165

What the project is doing

In the project's own words, from its summary on CORDIS.

Incidence and mortality of colorectal cancer (CRC) is the second leading cause of cancer death in Europe. With current screening programs in most European countries, many CRCs are detected in an early and curable stage with excellent prognosis. The current standard treatment for early CRC is surgical tumour removal. This is considered as overly invasive especially for the growing number of elderly and frail patients. Expanding technical possibilities of local tumour removal by flexible endoscopy along with initial data supporting its oncological safety open the way to organ preserving therapy.

This may result in avoiding surgery and improved patients´ quality of life (QoL). However, high-quality, long-term oncological outcome data of endoscopic removal as compared to surgery are lacking, and precise oncological risk criteria prior to the start of the therapy are urgently needed. The current project has two major aims: a) to assess oncological efficacy, safety, and patient QoL of local endoscopic removal of early CRC as compared to surgery in 3 randomized trials, and b) to develop and test criteria in this patient population to primarily identify high-risk lesions based on novel biomarkers, endoscopic imaging, and other clinical criteria, also within an artificial intelligence-guided treatment algorithm.

We propose to provide state-of-the-art assessment of new, sustainable, less invasive treatment modalities for early-stage CRC and determine patient preferences around these therapies. We will perform large, international head-to-head randomized clinical trials. These trials will allow carbon cost effectiveness analyses, biomarker research and development of clinical practice guidelines to carve out the next-generation best clinical practice for patients with early-stage CRC.

Our proposal aims at less invasive, sustainable organ-preserving therapies maintaining high oncological efficacy and helping physicians and patients to perform individual shared decision-making.

Topics

Who is involved

OrganisationCityCountryRole
Universitetet I OsloOsloNorwayCoordinator
Digestive Cancers Europe DiceBruxelles / BrusselBelgiumParticipant
Katholieke Universiteit LeuvenLeuvenBelgiumParticipant
Universiteit GentGentBelgiumParticipant
Universitat BaselBaselSwitzerlandAssociatedpartner
Universitaetsklinikum Hamburg-EppendorfHamburgGermanyParticipant
Fundacio De Recerca Clinic Barcelona-Institut D Investigacions Biomediques August Pi I SunyerBarcelonaSpainParticipant
Hospital Clinic De BarcelonaBarcelonaSpainThird party
Centre hospitalier universitaire de LimogesLimogesFranceParticipant
Azienda Sanitaria Locale Roma 6Albano Laziale RmItalyParticipant
Humanitas Mirasole SpARozzano (Mi)ItalyParticipant
Oslo Universitetssykehus HfOsloNorwayParticipant
Stiftelsen Magic Evidence EcosystemOsloNorwayParticipant
Gdanski Uniwersytet MedycznyGdanskPolandParticipant
Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie -Panstwowy Instytut BadawczyWarszawaPolandParticipant
Karolinska InstitutetStockholmSwedenParticipant
Sodersjukhuset ABStockholmSwedenParticipant
Veterans Education and Research Association of Northern New England, Inc.White River JunctionUnited StatesParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI